Epidermal growth factor receptor (EGFR) inhibitors are an increasingly important treatment option for metastasized cancer in patients. In addition to the pivotal role of EGFR in the development and progression of malignant tumors, EGFR is also important for proliferation and differentiation of the human epidermis and hair follicles. As a consequence, cutaneous side-effects are frequently observed during cancer therapy with EGFR inhibitors. During the first few weeks of treatment, acneiform eruptions are the earliest common side-effect. Xerosis and fissures are complications appearing in later treatment phases. Paronychia and alterations in hair growth are less common and generally seen after a longer period of treatment. We present an overview of the various cutaneous side-effects associated with EGFR inhibition and discuss their respective therapeutic options.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Severe cutaneous drug toxicity following disitamab vedotin treatment for metastatic gastric cancer: a case report.
Front Oncol
January 2025
Department of Pharmacy, Dongyang People's Hospital, Dongyang, Zhejiang, China.
Background: This study reports a case of severe cutaneous toxicity in a patient with metastatic gastric cancer induced by disitamab vedotin, emphasizing the need for careful monitoring and management in such treatments.
Case Presentation: A 71-year-old female was admitted to hospital complaining of serious rashes following the first cycle of disitamab vedotin regimen for metastatic gastric cancer. The doctor diagnosedtoxic epidermal necrolysis (TEN) induced by the drug.
The Efficacy of Cryoneurolysis on Chronic Pain in Patients with Knee Osteoarthritis; A Double-blinded Randomized Controlled Sham Trial.
Anesthesiology
January 2025
Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Background: The objective was to investigate if cryoneurolysis were superior to sham in reducing pain intensity in patients with chronic knee osteoarthritis. We hypothesized that cryoneurolysis was an effective and safe therapy to reduce chronic pain in patients with knee osteoarthritis.
Methods: The study was a randomized, double-blind, sham-controlled.
Hypersensitivity Reactions to Anticonvulsants.
Curr Allergy Asthma Rep
January 2025
Rochester Regional Health, Rochester, NY, USA.
Background: Antiepileptics are the mainstay of treatment for seizure management. Immediate and delayed hypersensitivity reactions associated with antiepileptics are common. It is important to differentiate between these reactions as management and prognosis varies.
View Article and Find Full Text PDFThe paradoxical activity of BRAF inhibitors: potential use in wound healing.
Arch Dermatol Res
January 2025
Department of Translational & Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India.
The area of wound healing presents a promising field of interest for clinicians as well as the scientific community. A major concern for physicians is the rising number of elderly people suffering from diabetes, leprosy, tuberculosis and the associated chronic wounds. While traditional therapies target basic wound care, innovative strategies that accelerate wound healing are needed.
View Article and Find Full Text PDFDrug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Fenofibrate Lipid Lowering Agent.
Skinmed
January 2025
Department of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
A 53-year-old woman presented with an eruption on her face and body for 2 weeks that had developed first on the face before spreading to the trunk and extremities. There was burning with sunlight exposure. Her medical conditions included diabetes mellitus, vitamin D deficiency, and hyperlipidemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!